Recipharm’s $22.3M blow-fill-seal expansion now operational at Kaysersberg, France, plant

The plant manufactures single-dose units and has an advanced aseptic process for sterile liquid packaging applications. (Recipharm)

Recipharm, a Swedish CDMO, said the new blow-fill-seal equipment that was part of the company’s $22.3 million (€18 million) investment at its Kaysersberg, France, facility is now operational.

The project added a new blow-fill-seal high-speed filling and packaging line, giving the facility a total of eight lines and increasing the plant’s manufacturing capacity by 200 million unidoses a year.

The plant manufactures single-dose units and has an advanced aseptic process for sterile liquid packaging applications. 

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

The construction project added 2,400 square meters to the facility, providing room for three machines that will eventually let Recipharm produce more than 1.2 billion unidoses a year.

“We have worked hard to develop a flexible service that can cater for even the most complex of projects,” Yves Buelens, general manager of the plant, said in a statement. “Adding the line to our facility will allow us to take on new customer projects more quickly, as well as continue to meet our current customers’ requirements. The additional space we’ve added also means we are also well positioned for further growth in line with future customer demand.”

Recipharm acquired the facility from Novartis’ Alcon unit for $19.7 million in 2015. 

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.